Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 410

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 410
---
 Iris’s common stock to date and does not intend to pay cash dividends prior to the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon Iris revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any cash dividends subsequent to a business combination will be within the discretion of the ParentCo board of directors at such time (as described in more detail below). Further, if Iris incurs any indebtedness, its ability to declare dividends may be limited by restrictive covenants it may agree to in connection therewith.

#### Liminatus
There is no public market for Liminatus’s common stock.

Liminatus has never declared or paid any cash dividends on our capital stock. Liminatus currently intends to retain any future earnings and does not expect to pay any dividends in the foreseeable future. Future cash dividends, if any, will be at the discretion of the ParentCo Board, subject to applicable law, and will depend upon, among other things, Liminatus’s future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors the ParentCo Board may deem relevant.

<div align='center'>225</div>

TABLE OF CONTENTS

### LEGAL MATTERS
Holland & Knight LLP has passed upon the validity of the securities of ParentCo offered by this proxy statement/prospectus and certain other legal matters related to this proxy statement/prospectus. Loeb & Loeb LLP has represented Liminatus in connection with the Business Combination.

### EXPERTS
The financial statements of Iris Acquisition Corp (formerly known as Tribe Capital Growth Corp I) as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023, appearing in this proxy statement/prospectus have been audited by Marcum LLP, an independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph relating to substantial doubt about the ability of Iris Acquisition Corp to continue as going concern as described in Note 1 to the financial statements) appearing elsewhere in this proxy statement/prospectus, and are included in reliance on such report given on the authority of such firm as an expert in accounting and auditing.

The consolidated financial statements of Liminatus Pharma, LLC and its subsidiaries as of December 31, 2023 and 2022, included in this proxy statement/prospectus have been audited